← Leaderboards
Joel B Nelson
University Of Pittsburgh At Pittsburgh
$928,618
Attributed
$1,579,375
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $378.8K · FY2005–13$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$1,579,375 · 3
By mechanism
R01$1,301,514 · 1
K08$181,840 · 1
R13$96,021 · 1
Top collaborators
- Zhou Wang4 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Zhou Wang$17,521,825
- Mark L. Zeidel$14,852,352
- Naoki Yoshimura$12,168,895
- Michael B Chancellor$7,406,767
- Robert H. Getzenberg$8,211,645
Others in their field
Top investigators on “Complex”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$385,971,304
- Chanza Baytop · Westat, Inc.$271,217,917
- David R. Weir · University Of Michigan At Ann Arbor$186,776,551
- Barton F Haynes · Duke University$162,931,717
Research focus
ComplexDrug ExposureCodeAffectAgedCoupled5a-Reductase InhibitionAnti-Inflammatory AgentsAgingBaseAndrogen ReceptorBenign Prostatic HypertrophyAndrogensBlindedAnti-InflammatoryAge EffectCelecoxibCellsChronicClinically SignificantClinical PracticeClinical ResearchClinical TrialsEpithelial
Grant awards (8)
Androgen signaling in benign prostatic hyperplasia (BPH)$300,326
R01 · FY2013 · DK
Androgen signaling in benign prostatic hyperplasia (BPH)$311,219
R01 · FY2012 · DK
Androgen signaling in benign prostatic hyperplasia (BPH)$311,219
R01 · FY2011 · DK
Androgen signaling in benign prostatic hyperplasia (BPH)$378,750
R01 · FY2010 · DK
Conference--Prouts Neck Prostate Cancer$25,000
R13 · FY2005 · CA
Conference--Prouts Neck Prostate Cancer$71,021
R13 · FY2004 · CA
ENDOTHELIN B RECEPTOR AND PROSTATE CANCER$90,920
K08 · FY2001 · CA
ENDOTHELIN B RECEPTOR AND PROSTATE CANCER$90,920
K08 · FY2000 · CA